Understand Your European Market Access Barriers
Identify reimbursement, payer and HTA barriers and define practical next steps.
White Paper: Market access for in-vitro diagnostic tests in Europe
Get insights from MTRC White Papers to advance your understanding of European market access for IVD tests
Recent news and posts
Germany increases budget for human genetic testing in 2026
On September 3, 2026, the National Association of Statutory Health Insurance Physicians (KBV) announced an increase in funding for human genetic diagnostic services reimbursed through the EBM catalog. The decision was adopted by the Evaluation Committee following the completion of its annual review of the volume of development in human genetic services.
As a result, an additional €29.4 million will be made available for human genetic diagnostics in 2026 within the morbidity-based total remuneration (MGV).
The funding increase follows a 2020 decision by the Evaluation Committee requiring the MGV allocated to human genetic services to be reviewed and adjusted annually over a five-year period. 2026 represents the final year of this scheduled review and adjustment process.
This news is just one of about 300 market access news and updates collected by our team in the premium subscription service MTRC Access Intelligence every week from more than 80 organizations. Access our paid service to stay on top of all developments, specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, six-week, no-obligation trial.